Platinum-Resistant Ovarian Carcinoma — Trials

Platinum-Resistant Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

109 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 56
Recruiting: 29
Ph III recruiting: 3
Growth YoY: —
Industry share: 48%
Top sponsor: National Cancer Institute (NCI)
Termination share: 52.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04678102	Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)(CREATIVE)	unknown	Phase 1	36	Seoul National University HospitalOTHER	1	Jun 26, 2023	clinicaltrials
NCT03542669	Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer	unknown	Phase 1	9	Peking University People's HospitalOTHER	1	Mar 2, 2022